Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.375 GBX | -2.17% | -.--% | -3.57% |
Apr. 17 | ReNeuron Group Reports CFO Resignation | MT |
Apr. 17 | ReNeuron CFO steps down to pursue other opportunities | AN |
Performance
1 day | -2.17% | ||
6 months | -30.41% | ||
Current year | -3.57% | ||
1 year | -56.45% | ||
3 years | -97.44% | ||
5 years | -98.75% | ||
10 years | -98.91% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Other Biotechnology & Medical Research
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
-2.17% | -.--% | -3.57% | -56.45% | 2.41M | ||
-4.39% | -6.15% | +17.96% | -9.27% | 44.96B | ||
+2.13% | +4.79% | +1.17% | +24.39% | 42.65B | ||
-1.00% | -0.38% | +46.34% | -8.52% | 41.85B | ||
+1.69% | +2.88% | -4.27% | +12.28% | 29.04B | ||
+0.11% | +2.06% | +11.42% | +57.70% | 26.08B | ||
-0.59% | -1.22% | -21.39% | -26.73% | 19.03B | ||
+1.61% | +4.68% | +4.86% | -0.48% | 12.75B | ||
-2.26% | -0.61% | +27.29% | +86.74% | 12.06B | ||
-0.86% | -2.29% | -3.50% | +19.28% | 11.75B | ||
-0.67% | +0.71% | +20.18% | +23.48% | 11.72B | ||
+0.07% | +1.47% | -2.60% | -6.18% | 9.67B | ||
-1.62% | +2.12% | +26.23% | -11.73% | 6.9B | ||
-0.10% | +0.98% | +8.59% | -30.93% | 6.7B | ||
-1.51% | -0.46% | +15.68% | +97.52% | 6.68B | ||
-0.53% | -7.34% | +29.88% | +43.99% | 6.15B | ||
Average | -0.27% | -0.34% | +10.89% | +13.44% | ||
Weighted average by Cap. | +0.26% | +0.26% | +12.68% | +12.97% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2024 | -3.57% | ||
2023 | -60.00% | ||
2022 | -89.33% | ||
2021 | -0.61% | ||
2020 | -44.44% | ||
2019 | +203.06% | ||
2018 | -73.87% | ||
2017 | -28.57% | ||
2016 | -12.50% | ||
2015 | -14.29% | ||
2014 | +16.47% | ||
2013 | +50.25% | ||
2012 | -54.80% | ||
2011 | -31.40% | ||
2010 | +6.61% | ||
2009 | +120.00% | ||
2008 | -86.59% | ||
2007 | -48.75% | ||
2006 | +54.44% | ||
2005 | -0.38% |
- Stock Market
- Equities
- RENE Stock
- Quotes ReNeuron Group plc